SavedAdd your journal

Journals / Marmara Medical Journal / 2019 / Cilt: 32 - Sayı: 3

Renal involvement in diffuse large B-cell lymphoma: A case report

Sinan DEMİRCİOĞLU
Ali DOĞAN
İrfan BAYRAM
Ufuk TELCİ
Mahsun ÖZÇELİK
Pages
144–146
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, it is recommended that CNS prophylaxis should be included in lymphoma treatment in cases of renal involvement.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma.
📊
Key Findings & Data:Approximately 40% of cases have extranodal involvement.
💡
Conclusion & Impact:Therefore, it is recommended that CNS prophylaxis should be included in lymphoma treatment in cases of renal involvement.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Approximately 40% of cases have extranodal involvement. Renal involvement is rare, however, it is associated with poor prognosis. Furthermore, renal involvement increases the risk of central nervous system (CNS) recurrence. Therefore, it is recommended that CNS prophylaxis should be included in lymphoma treatment in cases of renal involvement.

🔖

Cite This Article

DEMİRCİOĞLU, S., DOĞAN, A., BAYRAM, İ., TELCİ, U., ÖZÇELİK, M. (2022). Renal involvement in diffuse large B-cell lymphoma: A case report. Marmara Medical Journal, Cilt: 32 - Sayı: 3, 144–146. https://ajindex.com/articles/578414

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Morgan G, Vornanen M, Puitinen J, et al. Changing trends in the incidence of non-Hodgkin’s lymphoma in Europe. Biomed Study Group. Ann Oncol 1997;8 Suppl 2:49-54
  2. Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation—a population-based study of 1575 cases. Br J Haematol 2004;124:151-9
  3. Takahashi H, Tomita N, Yokoyama M, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer 2012;118:4166-72. doi:10.1002/ cncr.27381 [4] Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica 2011;96:1002-7. doi:10.3324/ haematol.2011.041277 [5] Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-804. doi:10.1200/JCO.2005.07.155 [6] Lehners N, Kramer I, Schwarzbich MA, Ho AD, Witzens-Harig M. Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era. Leuk Lymphoma 2016;57:2619-25. doi:10.3109/10428.194.2016.115 7869 [7] Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre-and post-rituximab. Ann Hematol 2011;90:809-18. doi:10.1007/s00277.010.1150-7 [8] Fletcher CD, Kahl BS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma 2014;55:2228-40. doi:10.3109/10428.194.2013.86 9326 [9] Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010;21:1046-52. doi:10.1093/annonc/mdp432 [10] Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 2012;23:1267-73. doi:10.1093/annonc/ mdr440 [11] Tomita N, Takasaki H, Ishiyama Y, et al. Intrathecal methotrexate prophylaxis and central nervous system relapse in pati